公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2014 | The impact of diabetes mellitus on early cervical cancer in Asia: A population-based cohort study | Kuo, Hung-Yang; Lin, Zhong-Zhe; Kuo, Raymond Nienchen; Shau, Wen-Yi; Lai, Chiu-Lin; Yang, Yen-Yun; Shao, Yu Yun; Hsu, Chiun; Chang, Wen-Fang; Chang, Ann-Lii; Yang, James Chih-Hsin; Lai, Mei-Shu; 鄭安理 | J. Clin. Oncol. | | | |
2015 | The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E) and of clinical factors in advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor mutations (EGFR mut) based on meta-analysis of 1,231 patients (pts) enrolled in 6 major randomized trials. | Lee, Chee; Davies, Lucy Claire; Wu, Yi-Long; Mitsudomi, Tetsuya; Inoue, Akira; Rosell, Rafael; Zhou, Caicun; Nakagawa, Kazuhiko; Throngprasert, Sumitra; Fukuoka, Masahiro; Gralla, Richard J.; Gebski, Val; Mok, Tony; Yang, James Chih-Hsin | J. Clin. Oncol. | | | |
2015 | TIGER-1: A Phase 2/3 Study of First Line Rociletinib or Erlotinib in EGFR-Mutant NSCLC | Camidge, Ross; Cappuzzo, Federico; Go, Jowell; Isaacson, Jeffrey; Litten, Jason; Park, Keunchil; Spigel, David R.; Spira, Alexander; Vergnenegre, Alain; Wolf, Juergen; Yang, James Chih-Hsin; Mok, Tony | J. Thorac. Oncol. | | | |
2015 | TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy. | Yang, James Chih-Hsin; Popat, Sanjay; Georgiou, Panos; Miyamoto, Emiko; Isaacson, Jeffrey D.; Wakelee, Heather A. | J. Clin. Oncol. | | | |